Citius Pharmaceuticals, Inc. — FY2019 Form 10-K
Reporting period: Fiscal year ended September 30, 2019; comparative figures are for the year ended September 30, 2018 unless otherwise noted. This is an annual filing, not a standalone fourth-quarter report. Citius is a clinical-stage specialty pharmaceutical company with no approved products and no product revenue.
Business context and pipeline
The company is developing Mino-Lok, an antibiotic lock therapy intended to salvage infected central venous catheters; Mino-Wrap, an antimicrobial wrap intended to reduce breast-implant infections; and Halo-Lido, a topical corticosteroid-lidocaine formulation for hemorrhoid symptoms.
- Mino-Lok: Phase 3 enrollment was underway. In September and October 2019, the FDA agreed to a revised primary endpoint, “time to catheter failure,” and an approximately 144-patient sample size, replacing the original 700-patient plan. The company reported the trial had reached 40% completion, triggering an interim futility analysis; the filing reports no analysis result. Mino-Lok has FDA Fast Track and QIDP designations.
- Mino-Wrap: Licensed in January 2019; the company planned preclinical work and announced an intention to pursue the FDA IND pathway.
- Halo-Lido: Development centers on a newer halobetasol-lidocaine formulation. The prior Phase 2a study used a different hydrocortisone-lidocaine formulation.
Financial performance and position
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $8.60 million | $6.56 million |
| General and administrative expense | $6.29 million | $6.45 million |
| Total operating expenses / operating loss | $15.60 million | $13.79 million |
| Net loss | $15.56 million | $12.54 million |
| Net loss per share, basic and diluted | $0.77 | $1.17 |
| Cash used in operating activities | $12.44 million | $11.32 million |
R&D expense increased about 31%, primarily due to Mino-Lok Phase 3 activity and higher Halo-Lido spending. Net loss increased about 24%; the prior year included $1.27 million of other income from an FDA fee refund and reversal of an accrued liability. Per-share loss declined as weighted-average shares increased substantially. Gross and operating margins are not meaningful because the company reported no revenue.
At September 30, 2019, cash and cash equivalents were $7.89 million, working capital was $3.33 million, total current assets were $7.94 million, and current liabilities were $4.61 million. Total assets were $28.99 million and stockholders’ equity was $24.38 million. Related-party notes payable were $172,970; the filing does not identify material conventional long-term borrowing. Cash declined $1.29 million during the year despite $11.15 million of net financing proceeds, principally from equity offerings. The company reported no off-balance-sheet arrangements.
Common shares outstanding increased from 16.20 million at September 30, 2018 to 28.93 million at September 30, 2019. The company also disclosed 25.49 million outstanding warrant shares and 1.77 million option shares, creating significant potential dilution.
Outlook, liquidity, and significant risks
Management expected available capital to support operations through March 2020 and said additional capital would be needed. The filing states that financing plans depend on raising additional funds and gives no assurance that financing will be available on acceptable terms or in time. The independent auditor’s report highlights substantial doubt about the company’s ability to continue as a going concern; the financial statements contain no adjustments for a possible failure to continue operations.
- Key risks include clinical-trial failure or delay, FDA approval uncertainty, dependence on external clinical and manufacturing providers, and the need for additional financing. The company had no approved products, sales, or internal sales and manufacturing infrastructure.
- Nasdaq notified the company in October 2019 that its share price had failed the $1.00 minimum bid-price requirement. The stated deadline to regain compliance was April 27, 2020, with a possible additional compliance period subject to conditions.
- Management reported disclosure controls and internal control over financial reporting were effective as of September 30, 2019. The auditor expressed an unqualified opinion on the financial statements while emphasizing the going-concern uncertainty.
- No material litigation was reported. Other notable items include the 76-month office lease, with disclosed future base rents, and planned adoption of lease accounting that management estimated would add approximately $1.14 million in right-of-use assets and lease liabilities.
Important facts for investors to verify
- Current cash runway, spending needs, and whether subsequent financing was completed on terms that avoid materially greater dilution.
- The Mino-Lok interim futility analysis outcome, enrollment progress, and whether the revised endpoint and sample size remain acceptable to the FDA.
- Updated development timelines, costs, and regulatory plans for Mino-Wrap and Halo-Lido.
- Nasdaq bid-price compliance status and the fully diluted share count, including outstanding warrants and options.
- Whether any subsequent events changed the going-concern assessment or the company’s ability to fund operations and clinical programs.